Research peptides are short chains of amino acids, chemically synthesised to a defined sequence and supplied as lyophilised powder for laboratory investigation. They sit between small molecules and proteins in size, and they are used in vitro to probe receptors, enzymes and signalling pathways. This guide explains what research peptides are, how they are made and purified, how the main classes differ, and what quality documentation a laboratory should expect. Everything here is written for research use only.
Key takeaways
- A peptide is a chain of amino acids joined by peptide (amide) bonds. Chains of fewer than about twenty residues are oligopeptides; beyond roughly fifty residues, or 10,000 Da, the convention shifts to calling the molecule a protein.
- Therapeutic and research peptides typically fall in the 500–5,000 Da range, which is why they behave unlike both small molecules and antibodies.
- Almost all research peptides are made by solid-phase peptide synthesis, a repeated deprotect–couple–wash cycle introduced by Merrifield in 1963, followed by cleavage, RP-HPLC purification and lyophilisation.
- Peptides are chemically fragile: the amide backbone is hydrolysable and enzymatically cleavable, which drives most of the engineering seen in modern analogues — D-amino acids, Aib substitutions, amidation and fatty-acid acylation.
- The main research classes are metabolic/incretin, growth-hormone axis, repair and recovery, cosmetic and skin, immune and antimicrobial, longevity and bioregulator, mitochondrial, nootropic and reproductive.
- Quality is established by two orthogonal measurements — RP-HPLC for purity and mass spectrometry for identity — reported on a per-batch certificate of analysis.
- Research peptides are not medicines. They are laboratory reagents supplied for in-vitro research, not for human or veterinary use.
What are research peptides?
Research peptides are chemically synthesised amino-acid chains supplied to laboratories as reagents for in-vitro and preclinical investigation. They are not formulated medicines, are not sterile injectables, and carry no marketing authorisation. Their purpose is to let investigators apply a defined molecular sequence to a biological system and observe what happens.
The category covers a wide range of molecules: endogenous hormones reproduced synthetically, fragments of larger proteins, engineered analogues designed to resist degradation, and entirely novel sequences from medicinal chemistry programmes. What unites them is that the active principle is a sequence of amino acids rather than a small organic scaffold.
Peptides occupy a distinctive middle ground. They are large enough to make specific, high-affinity contacts across an extended receptor surface — something a small molecule struggles to do at class B GPCRs — but small enough to be made by chemical synthesis rather than cell culture, and to be characterised precisely by mass spectrometry.
Peptide chemistry: bonds, termini and size
A peptide bond is an amide formed by condensation between the carboxyl group of one amino acid and the amino group of the next, releasing water. Repeat that reaction and you get a chain with a free amine at one end — the N-terminus — and a free carboxyl at the other, the C-terminus. Sequences are conventionally written N-terminus first.
Size terminology is conventional rather than absolute. Chains of fewer than twenty residues are usually called oligopeptides; longer unbranched chains are polypeptides; and once a polypeptide reaches roughly 10,000 Da, or about fifty residues, it is customarily described as a protein. Therapeutic and research peptides typically fall between 500 and 5,000 Da.
| Term | Residues | Approx. mass | Representative research compound |
|---|---|---|---|
| Dipeptide | 2 | < 300 Da | Vilon (Lys-Glu) |
| Tripeptide | 3 | < 450 Da | GHK-Cu; KPV (Lys-Pro-Val) |
| Tetrapeptide | 4 | < 600 Da | Epitalon (Ala-Glu-Asp-Gly) |
| Oligopeptide | 5–20 | 0.6–2.5 kDa | BPC-157 (15); MOTS-c (16) |
| Polypeptide | 20–50 | 2.5–5.5 kDa | Semaglutide (31); tirzepatide (39) |
| Protein | > 50 | > 10 kDa | Somatropin (191) |
How research peptides are manufactured
Nearly all research peptides are produced by solid-phase peptide synthesis (SPPS), the method Merrifield published in 1963 and for which he later received the Nobel Prize. The principle is elegant: anchor the growing chain to an insoluble resin bead so that excess reagents and by-products can simply be washed away between steps.
The two protecting-group strategies
Two chemistries dominate. In the Fmoc/tBu strategy the temporary N-terminal protecting group is base-labile fluorenylmethyloxycarbonyl, side-chain groups are acid-labile, and the finished chain is released with trifluoroacetic acid plus scavengers. In the older Boc/benzyl strategy the temporary group is acid-labile Boc and final cleavage uses anhydrous hydrogen fluoride. Fmoc chemistry dominates modern research-scale synthesis because it avoids handling HF.
Why the crude product is never clean
Each coupling step is a chemical reaction with a yield below 100%. A chain that fails to couple in one cycle but couples in the next becomes a deletion sequence — the target peptide minus one residue. Because efficiency compounds over the whole synthesis, longer sequences and aggregation-prone sequences give markedly dirtier crude material, which is why purification and analytical verification are not optional extras.
Common modifications and why they exist
The amide backbone that makes peptides so specific also makes them fragile: amide bonds hydrolyse and are cleaved by peptidases, giving many native peptides half-lives measured in minutes. Almost every structural modification you will encounter in a research catalogue is an answer to that problem.
- D-amino acid substitution. Swapping an L-residue for its mirror image at a protease-susceptible site prevents recognition by stereospecific enzymes. Seen in triptorelin (D-Trp6) and the Szeto-Schiller peptides.
- Aib and other α,α-disubstituted residues. α-aminoisobutyric acid at position 2 of an incretin blocks dipeptidyl peptidase-4 cleavage and stiffens the helix. Used in semaglutide, tirzepatide and retatrutide.
- C-terminal amidation. Replacing the free carboxylate with an amide removes a charge and a carboxypeptidase substrate. Common in melanocortins, amylin analogues and many bioregulators.
- N-terminal acetylation. Caps the free amine against aminopeptidases; seen in acetyl octapeptide-3 and the acetylated TB-500 fragment.
- Fatty-acid acylation. Attaching a C16–C20 chain, often through a γ-glutamate and AEEA spacer, gives reversible albumin binding and extends circulating time from minutes to days.
- PEGylation. Covalent polyethylene glycol increases hydrodynamic radius and slows renal filtration — the difference between MGF and PEG-MGF.
- Cyclisation and disulfide bonds. Constraining the backbone reduces conformational entropy and can raise both potency and stability, as in melanotan II and the amylin family.
- Metal chelation. A few peptides are supplied as metal complexes because the metal is part of the pharmacophore — GHK-Cu and AHK-Cu are copper(II) complexes.
The main classes of research peptides
Research peptides are usually grouped by the biological system they act on rather than by chemistry. The map below covers the classes a UK research supplier typically stocks, and each has a dedicated guide in the library further down this page.
| Class | Principal targets studied | Example compounds | Typical size |
|---|---|---|---|
| Metabolic / incretin | GLP-1R, GIPR, GCGR, amylin/CTR | Semaglutide, tirzepatide, retatrutide, cagrilintide, survodutide, mazdutide, liraglutide | 30–40 residues |
| Growth hormone axis | GHRH-R, GHS-R1a, IGF-1R | Sermorelin, tesamorelin, CJC-1295, ipamorelin, GHRP-2, GHRP-6, hexarelin, IGF-1 LR3, MGF | 5–70 residues |
| Repair and recovery | Angiogenesis, actin dynamics, growth factors | BPC-157, TB-500, ARA-290, Wolverine/GLOW/KLOW blends | 7–15 residues |
| Cosmetic and skin | Collagen synthesis, copper transport, SNARE complex | GHK-Cu, AHK-Cu, Pal-KTTKS, acetyl octapeptide-3 | 3–10 residues |
| Immune and antimicrobial | Toll-like receptors, membranes, melanocortin | Thymosin alpha-1, LL-37, KPV | 3–37 residues |
| Longevity / bioregulator | Gene expression, tissue-specific regulation | Epitalon, vilon, thymalin, pinealon, cortagen, cardiogen | 2–4 residues |
| Mitochondrial | Cardiolipin, AMPK, mitochondrial-derived peptides | MOTS-c, SS-31, humanin | 4–24 residues |
| Nootropic / neurological | BDNF/TrkB, GABAergic, opioid systems | Semax, selank, DSIP, P21, PE-22-28 | 5–15 residues |
| Melanocortin | MC1R–MC5R | Melanotan 1, melanotan II, PT-141 | 7–13 residues |
| Reproductive / HPG | Kisspeptin receptor, GnRH-R, LH/FSH receptors | Kisspeptin-10, gonadorelin, triptorelin, hCG, HMG | 10 residues to glycoproteins |
Quality: purity, identity and the certificate of analysis
Because synthesis is imperfect and peptides degrade, the only meaningful statement about a vial’s contents is a per-batch analytical result. Two orthogonal measurements are needed, and neither substitutes for the other.
RP-HPLC — how much?
Reverse-phase HPLC separates by hydrophobicity on a C18 column with a water/acetonitrile gradient, detecting at 214–220 nm where the peptide bond absorbs. Purity is the main peak’s area as a percentage of total peak area. It cannot see counter-ions, water or co-eluting isomers.
Mass spectrometry — which molecule?
Electrospray or MALDI ionisation gives a mass measurement that is compared against the calculated mass for the sequence. It confirms identity precisely but is a poor quantitative tool and cannot distinguish isomers such as racemised residues or scrambled disulfides.
ICH Q6B, the international guideline on specifications for biological products, makes the underlying point explicitly: absolute purity is difficult to determine, results are method-dependent, and purity should therefore be assessed using a combination of analytical procedures rather than a single number.
GenoPept publishes per-batch third-party certificates covering HPLC purity and mass spectrometry identity at our COA page.
Handling, reconstitution and storage
Lyophilised peptide is the stable state; solution is the vulnerable one. The freeze-dried cake is hygroscopic, so the main threats before reconstitution are moisture and temperature. After reconstitution, hydrolysis, oxidation, deamidation, aggregation and surface adsorption all become live concerns.
- Equilibrate before opening. Let a cold vial reach room temperature so moisture does not condense onto the cake.
- Add diluent gently. Run bacteriostatic or sterile water down the vial wall rather than onto the powder, and never vortex — shear and foaming drive aggregation.
- Label immediately. Compound, batch, concentration, date. An unlabelled reconstituted vial is unusable data.
- Refrigerate solutions, freeze the powder. Sealed lyophilised material belongs at −20 °C; working solutions at 2–8 °C for short periods.
- Aliquot before freezing. Repeated freeze–thaw is one of the most reliable ways to destroy a peptide preparation.
- Protect from light. Tryptophan, tyrosine and metal-complexed peptides are photosensitive.
Legal and compliance context in the UK
Research peptides supplied for laboratory use are reagents, not medicines. They carry no marketing authorisation, are not manufactured to pharmaceutical sterility standards, and must not be used for diagnosis or treatment. Suppliers operating on a research-use-only basis typically require purchasers to attest to that at checkout.
Some compounds sit in additional regulatory categories regardless of how they are supplied. In the UK, certain hormone products — including somatropin and human chorionic gonadotropin — are controlled drugs under the Misuse of Drugs Act 1971, and their supply is regulated accordingly. Import can also engage customs and Trading Standards requirements. Our dedicated guide covers this in detail; this is general information, not legal advice.
The full GenoPept research guide library
Every class introduced above has a detailed guide. Use this as the index to the whole library.
Laboratory fundamentals
Metabolic and incretin peptides
Growth hormone axis
Repair, recovery and blends
Cosmetic, skin and immune peptides
Longevity, bioregulators and mitochondria
Neurological and reproductive peptides
Research peptides in the GenoPept store
Frequently asked questions
What are research peptides?
Research peptides are chemically synthesised chains of amino acids supplied to laboratories as reagents for in-vitro and preclinical investigation. They are typically 500–5,000 Da, made by solid-phase synthesis, purified by HPLC and supplied as lyophilised powder in sealed vials. They are not medicines and are not for human or veterinary use.
What is the difference between a peptide and a protein?
The distinction is conventional rather than chemical. Chains of fewer than about twenty residues are called oligopeptides, longer unbranched chains are polypeptides, and once a polypeptide exceeds roughly fifty residues or 10,000 Da it is customarily called a protein. Both are built from the same amino acids joined by the same peptide bonds.
How are research peptides made?
Almost all are made by solid-phase peptide synthesis, introduced by Merrifield in 1963. The growing chain is anchored to a resin bead and extended one residue at a time through a repeated deprotect–couple–wash cycle. The finished chain is cleaved from the resin, purified by preparative reverse-phase HPLC, freeze-dried into a cake and tested by HPLC and mass spectrometry.
Why are peptides lyophilised rather than supplied in solution?
The amide backbone hydrolyses in water and is attacked by residual enzymatic activity, so a peptide in solution has a far shorter usable life than the same peptide as a dry powder. Freeze-drying removes the water, leaving a stable porous cake that dissolves readily when a diluent is added. The trade-off is that the cake is hygroscopic and must be kept sealed and dry.
Why do so many research peptides carry a fatty acid or a D-amino acid?
Both are stability engineering. A D-amino acid at a protease-susceptible position blocks stereospecific enzymes from cleaving there. A C16–C20 fatty-acid chain binds reversibly to serum albumin, creating a circulating depot that slows renal clearance and extends duration from minutes to days. Aib substitution, C-terminal amidation and PEGylation serve related purposes.
What quality documentation should a research peptide come with?
A per-batch certificate of analysis showing appearance, an HPLC chromatogram with full method conditions and an integration table, a mass spectrometry result comparing observed and calculated mass, water content and ideally net peptide content. The batch number on the certificate must match the vial, and third-party testing carries more weight than an unattributed in-house figure.
Are research peptides legal in the UK?
Research peptides supplied for laboratory use are reagents rather than medicines and are generally supplied on a research-use-only basis with a purchaser attestation. Some compounds sit in additional categories: somatropin and human chorionic gonadotropin, for example, are controlled drugs under the Misuse of Drugs Act 1971 and their supply is regulated. This is general information, not legal advice.
How should research peptides be stored?
Keep sealed lyophilised vials at −20 °C, desiccated and protected from light. Once reconstituted, refrigerate at 2–8 °C and use within a short working window, or aliquot into low-binding tubes and freeze so no aliquot is thawed twice. Avoid vortexing, repeated freeze–thaw and prolonged light exposure, all of which accelerate aggregation and degradation.
References
- Merrifield RB. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. Journal of the American Chemical Society. 1963;85(14):2149–2154. DOI
- Wang L, Wang N, Zhang W, et al. Therapeutic peptides: current applications and future directions. Signal Transduction and Targeted Therapy. 2022;7:48. Nature
- Mant CT, Chen Y, Yan Z, et al. HPLC analysis and purification of peptides. Methods in Molecular Biology. 2007;386:3–55. Springer
- Fenn JB, Mann M, Meng CK, Wong SF, Whitehouse CM. Electrospray ionization for mass spectrometry of large biomolecules. Science. 1989;246(4926):64–71. PubMed
- Karas M, Hillenkamp F. Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons. Analytical Chemistry. 1988;60(20):2299–2301. PubMed
- International Council for Harmonisation. ICH Q6B: Specifications — Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. Adopted 10 March 1999. ICH
Research peptides, batch-verified and UK-dispatched
GenoPept supplies lyophilised research peptides across every class described on this page, each with a per-batch third-party certificate of analysis covering HPLC purity and mass spectrometry identity, strictly for laboratory research.